Baader Bank Aktiengesellschaft Has $205,000 Holdings in Becton, Dickinson and Company (NYSE:BDX)

Baader Bank Aktiengesellschaft trimmed its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 8.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 905 shares of the medical instruments supplier’s stock after selling 80 shares during the period. Baader Bank Aktiengesellschaft’s holdings in Becton, Dickinson and Company were worth $205,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Livelsberger Financial Advisory acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth about $26,000. Ashton Thomas Securities LLC acquired a new position in Becton, Dickinson and Company during the third quarter worth approximately $33,000. Tompkins Financial Corp raised its stake in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 46 shares during the period. Sound Income Strategies LLC lifted its position in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares during the last quarter. Finally, Kennebec Savings Bank bought a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $46,000. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Trading Down 0.3 %

BDX stock opened at $247.63 on Friday. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $250.91. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. The company’s 50-day simple moving average is $230.06 and its 200 day simple moving average is $233.66. The company has a market capitalization of $71.82 billion, a PE ratio of 41.69, a price-to-earnings-growth ratio of 1.79 and a beta of 0.39.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the firm earned $3.42 earnings per share. The business’s revenue for the quarter was up 6.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.41 earnings per share for the current year.

Becton, Dickinson and Company declared that its board has approved a share repurchase program on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.68%. Becton, Dickinson and Company’s payout ratio is 70.03%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Roland Goette sold 4,483 shares of the firm’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $221.01, for a total value of $990,787.83. Following the transaction, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at $5,380,488.45. This trade represents a 15.55 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Shan sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the sale, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 9,844 shares of company stock worth $2,210,716. Company insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Piper Sandler raised their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus target price of $283.00.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.